Latus Bio, Inc. has presented new preclinical findings demonstrating improved delivery of genetic material to kidney and central nervous system tissues using proprietary engineered adeno-associated virus capsids. Disclosed on October 30, 2026, at the 33rd Annual Congress of the European Society of Gene and Cell Therapy in Hamburg, Germany, the results included delivery to approximately 80% of kidney glomeruli and transduction of around 40% to 60% of cortical neurons in non-human primate studies.
The findings address two longstanding challenges in gene therapy development: reaching disease-relevant cells efficiently and limiting exposure in tissues where therapeutic gene expression is not intended. Latus Bio reported that its kidney-targeting AAV-Kd variants and pan-neuronal AAV-PN capsid demonstrated favourable delivery characteristics compared with conventional AAV9 under the evaluated experimental conditions. Separate conference presentations provided further evidence supporting the company’s Huntington’s disease and CLN2 Batten disease programmes.
However, the new capsid findings are preclinical and do not establish treatment efficacy or safety in human patients. The percentages describe measured distribution or cellular transduction in experimental models, not disease reversal or therapeutic response rates. Their longer-term importance will depend on whether the engineered vectors can deliver functional treatments at clinically acceptable doses while maintaining predictable manufacturing and safety characteristics.
What did Latus Bio’s ESGCT 2026 presentations reveal about engineered AAV delivery to the brain and kidneys?
Latus Bio presented four scientific posters covering new gene delivery technologies and investigational therapeutic programmes. The research included pan-neuronal capsids, kidney-targeting variants, a Huntington’s disease programme involving MSH3 suppression and a CLN2 Batten disease therapy intended to restore tripeptidyl peptidase 1 activity. The studies reflect a platform strategy that combines tissue-specific vector engineering with genetic payloads selected for particular diseases.
The newly disclosed AAV-PN capsid was designed to deliver genetic material broadly to neurons across the brain and spinal cord. Following intracerebroventricular administration in adult non-human primates, the vector produced widespread central nervous system distribution and transgene expression. Latus Bio also reported substantially less off-target expression in peripheral tissues compared with the AAV9 reference conditions.
A separate group of engineered AAV-Kd capsids was designed for kidney delivery following intravenous administration. The most fully characterised candidate, AAV-Kd-1, demonstrated transduction across glomerular and tubular structures, including several cell populations relevant to inherited and acquired kidney diseases. These findings suggest that vector engineering may address limitations associated with naturally occurring AAV capsids, which have not consistently delivered high levels of expression across all important renal cell populations.
The presentation also highlighted how Latus Bio is applying its delivery platform to therapeutic candidates rather than focusing solely on vector discovery. LTS-201 targets a biological mechanism associated with Huntington’s disease progression, while LTS-101 is intended to restore a deficient enzyme in CLN2 Batten disease. These programmes provide potential routes for testing whether delivery improvements translate into meaningful therapeutic outcomes.
How did the AAV-PN capsid achieve widespread neuronal transduction across the brain and spinal cord?
The AAV-PN programme focuses on a fundamental challenge in neurological gene therapy: delivering enough genetic material to the relevant neurons throughout the central nervous system. Many neurological disorders affect distributed networks rather than a single small anatomical region. A treatment that reaches only a limited subset of cells may therefore fail to influence the biological processes responsible for disease progression.
Latus Bio evaluated its pan-neuronal capsid in adult non-human primates following low-dose intracerebroventricular administration. The company reported transduction of approximately 40% to 60% of neurons across the cortex and up to 40% of spinal cord motor neurons, based on expression of a fluorescent reporter protein. These measurements indicate that the vector reached a substantial proportion of selected neuronal populations under the study conditions.
The company also reported substantially higher central nervous system transgene expression than observed with AAV9 administered through either intracerebroventricular or intravenous routes in the relevant comparisons. This distinction matters because the route of administration affects how much vector reaches the brain and spinal cord. AAV-PN’s reported performance should therefore be interpreted in the context of both its engineered capsid and the selected delivery method.
However, neuronal transduction is not equivalent to correction of a neurological disorder. A fluorescent reporter demonstrates that a vector has delivered and expressed experimental genetic material, but a therapeutic payload may have different expression and biological requirements. Additional research will need to establish whether the observed distribution provides sufficient exposure to produce clinical benefit.
The reported 40% to 60% cortical transduction also should not be interpreted as uniform delivery throughout every region of the brain. Different neuronal populations may have distinct accessibility and receptor characteristics. Disease-specific development must determine whether the cells reached by the capsid are the same cells that require treatment.
Why could reduced liver and dorsal root ganglion exposure improve the development of CNS gene therapies?
A major limitation of some AAV delivery strategies is that vectors can reach tissues outside the intended treatment site. Following systemic administration, substantial vector material may accumulate in organs such as the liver. Certain neurological administration approaches can also expose dorsal root ganglia, which contain sensory neuron cell bodies, to high vector concentrations.
These exposures are relevant because AAV-based gene therapies have been associated with serious adverse events in particular development programmes. Regulatory safety discussions have identified concerns including liver injury, immune-mediated reactions and dorsal root ganglion abnormalities. The risk depends on the capsid, dose, therapeutic payload, administration route and patient population.
Latus Bio reported that AAV-PN produced substantially lower off-target transgene expression in peripheral tissues, including the liver and dorsal root ganglia, than the evaluated AAV9 comparators. This may be relevant to future safety development because limiting unnecessary expression could reduce certain sources of biological exposure. However, reduced transgene expression is not itself proof of lower clinical toxicity.
Vector genomes, immune responses and transgene expression represent different biological measurements. A capsid could produce less expression in one tissue while still generating immune recognition or other unwanted effects. Proper evaluation requires histopathology, clinical laboratory measurements and other toxicological assessments, not simply a comparison of fluorescent reporter activity.
The relationship between lower vector dose and safety also needs careful assessment. More efficient delivery could potentially reduce the amount of vector required to achieve therapeutic activity, but the minimum effective dose will depend on the disease and genetic payload. Latus Bio has not demonstrated that AAV-PN produces a lower rate of adverse events in treated patients.
What makes AAV-Kd-1’s approximately 80% glomerular targeting important for kidney gene therapy?
The kidney contains several highly specialised cell types with different roles in filtration, transport and maintenance of fluid and electrolyte balance. Many kidney diseases involve particular cellular compartments rather than the entire organ uniformly. This creates a challenge for gene therapy because a vector must reach the relevant cells while avoiding excessive delivery elsewhere.
AAV-Kd-1 was evaluated following low-dose intravenous administration in adult non-human primates. Latus Bio reported transduction in approximately 80% of glomeruli across both kidneys, demonstrating broad coverage of the kidney’s filtration structures. The company also identified expression in several distinct glomerular cell populations.
However, transduction of 80% of glomeruli does not mean that 80% of every cell type within those structures received the vector. A glomerulus contains multiple interacting cell populations, and each may exhibit different delivery efficiency. The separate cell-specific measurements are therefore essential for understanding the actual biological coverage.
Latus Bio reported greater than 30% transduction in podocytes, glomerular endothelial cells and mesangial cells. These populations contribute to filtration barrier function, structural support and regulation of glomerular activity. The ability to reach them through systemic administration could potentially support development of genetic medicines for diseases involving the glomerular compartment.
Nevertheless, a high proportion of transduced cells does not demonstrate restoration of kidney function. The experimental measurements used a delivery system to evaluate expression rather than a validated disease-specific therapeutic intervention. Future studies must determine whether an appropriate genetic payload can modify the relevant disease process at tolerable exposure levels.
How could engineered renal capsids expand treatment opportunities beyond glomerular kidney disorders?
The AAV-Kd research also investigated vector delivery to kidney tubules. These structures are responsible for extensive processing of filtered material, including reabsorption and secretion of substances needed to maintain normal physiological balance. Genetic disorders involving tubular transport or metabolism can therefore produce serious kidney dysfunction.
Latus Bio reported transduction of up to approximately 30% of proximal tubular cells with AAV-Kd-1. It also observed more than twice the level of transduction in distal tubules and collecting ducts compared with intravenous AAV9 under the evaluated conditions. These results suggest that the engineered capsid may provide access to several renal compartments rather than concentrating exclusively on glomerular cells.
The distinction is important because an effective gene therapy for one kidney disease may need to reach entirely different cells from a treatment developed for another condition. A capsid that transduces multiple relevant populations could offer flexibility for future therapeutic programmes. However, broadly distributed kidney expression may not be optimal for every disease, particularly if gene activity is needed only in one cell type.
Latus Bio also described additional emerging kidney-targeting variants with promising liver-detargeting characteristics. These candidates remain under investigation, and the company has not disclosed complete comparative performance data for every variant. The development objective is to identify delivery systems that combine adequate renal activity with reduced unnecessary exposure elsewhere.
No specific kidney disease clinical trial was announced in connection with the ESGCT findings. The results therefore expand the potential applications of the company’s platform but do not establish a new clinical-stage renal therapy. Disease-specific proof of concept will require appropriate therapeutic constructs and supporting efficacy studies.
How does LTS-201 use MSH3 suppression to investigate Huntington’s disease progression?
Huntington’s disease is an inherited neurodegenerative disorder associated with an expanded CAG repeat in the HTT gene. Although individuals inherit a particular repeat length, additional expansion can occur in certain cells over time through a process known as somatic instability. Research has increasingly implicated this process in the timing and progression of neurological disease.
MSH3 is a DNA mismatch repair protein involved in mechanisms that contribute to somatic repeat expansion. Latus Bio is developing LTS-201 to reduce MSH3 expression using an artificial microRNA delivered through its engineered AAV-DB-3 capsid. The vector is designed to target medium spiny neurons in the striatum and selected cortical projection neurons affected by Huntington’s disease.
At ESGCT 2026, the company presented additional findings from a research programme also published in Nature Communications on October 28. In non-human primates, the candidate produced dose-dependent reductions in MSH3 messenger RNA, ranging from approximately 48% to 94% across the evaluated doses. Experiments in a Huntington’s disease mouse model also demonstrated reductions in somatic CAG repeat instability.
The peer-reviewed study incorporated a computational model developed using human Huntington’s disease data. The model estimated how changes in MSH3 activity and the proportion of affected neurons might influence disease progression. However, the resulting projections are modelled scenarios rather than measured clinical benefits.
The findings provide mechanistic support for investigating MSH3 suppression as a disease-modifying strategy. They do not establish that LTS-201 delays Huntington’s disease onset, preserves neurological function or extends survival in patients. Those questions will require an appropriately designed human development programme.
Why must predictions of delayed Huntington’s disease progression be distinguished from clinical results?
The LTS-201 modelling study connects preclinical MSH3 suppression with estimates of potential benefit across different inherited CAG repeat lengths and treatment ages. This approach is scientifically useful because it makes assumptions about target engagement and disease progression explicit. It can help researchers select doses and identify which patient populations might offer the clearest opportunities for future evaluation.
However, computational models depend on the accuracy of their underlying biological assumptions. The relationship between somatic instability, neuronal dysfunction and clinical progression may differ between individuals. A treatment could alter the intended molecular process without producing the magnitude of benefit projected by the model.
The reported 94% maximum MSH3 messenger RNA reduction was measured in experimental non-human primate neurons, not in patients with Huntington’s disease. It should therefore not be described as a 94% reduction in clinical disease activity. Similarly, modelled slowing of progression cannot be treated as an observed patient outcome.
The peer-reviewed publication strengthens confidence that the biological research has undergone external scientific assessment. Nevertheless, peer review does not replace prospective clinical testing. The next stage must examine safety, target engagement and clinically meaningful endpoints in affected individuals.
For Latus Bio, the modelling strategy may support rational clinical development, but its commercial significance remains conditional. A disease-modifying treatment would represent a major advance, yet the probability of achieving that outcome cannot be determined from preclinical target suppression alone.
What did the LTS-101 results reveal about enzyme replacement through gene therapy for CLN2 Batten disease?
Latus Bio also presented preclinical information concerning LTS-101, its investigational gene therapy for late-infantile neuronal ceroid lipofuscinosis type 2, commonly known as CLN2 Batten disease. The disorder is associated with deficiency of tripeptidyl peptidase 1, or TPP1, an enzyme involved in lysosomal protein processing. Insufficient enzyme activity contributes to progressive neurological deterioration.
LTS-101 uses the company’s engineered Ep+ capsid to deliver a functional human TPP1 gene. The intended approach is to enable transduced cells to produce the missing enzyme, potentially providing a sustained source of therapeutic activity. Its development rationale differs from treatments requiring repeated administration of externally manufactured enzyme.
The ESGCT presentation included findings from a non-human primate study conducted under good laboratory practice toxicology conditions. Latus Bio reported that LTS-101 was well tolerated during the six-month observation period and maintained potentially therapeutic TPP1 protein concentrations in cerebrospinal fluid. These measurements support continued investigation but do not establish clinical effectiveness.
LTS-101 has received US FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations, and its Investigational New Drug application has been cleared. These milestones support clinical development but do not constitute marketing approval. The October announcement did not disclose new human efficacy results for LTS-101.
For patients with CLN2 disease, durability and central nervous system distribution will be central development considerations. A therapy that provides sustained enzyme activity could potentially reduce the need for repeated interventions, but the clinical effect and long-term safety must be demonstrated. The non-human primate findings provide supporting evidence for that investigation.
How does the $97 million Series A financing support Latus Bio’s platform and therapeutic development strategy?
Latus Bio announced completion of a $97 million Series A financing in May 2026, including a $43 million extension led by 8VC. Other participating investors included DCVC Bio, BioAdvance, Benjamin Franklin Technology Partners and additional healthcare investors. The financing was intended to support development of the company’s lead neurological gene therapy programmes and broader capsid discovery activities.
This funding provides context for the company’s simultaneous work across central nervous system and kidney delivery. Developing capsids and translating them into therapeutic products require substantial resources for laboratory research, animal studies, manufacturing and regulatory preparation. Multiple programmes also create competing demands on available capital.
The company’s strategy is to improve delivery efficiency so that clinically relevant activity may be achievable with lower vector doses. If successful, such improvements could influence manufacturing requirements because fewer vector genomes might be needed for each treatment. However, the October findings do not quantify a reduction in commercial production costs or establish clinical dose savings.
The new kidney and pan-neuronal capsids may also create potential partnering opportunities. Pharmaceutical developers working on different genetic diseases could investigate whether these vectors offer suitable delivery characteristics for their therapeutic payloads. Nevertheless, Latus Bio did not announce a new licensing agreement or commercial transaction associated with the ESGCT presentations.
As a privately held biotechnology company, Latus Bio does not provide the same regular public financial disclosures required of listed companies. Its available funding information therefore does not establish its current cash balance or the exact duration of its development runway. Future financing needs will depend on the pace and scope of its clinical programmes.
What will determine whether Latus Bio’s ESGCT 2026 findings translate into human gene therapies?
The first requirement is additional validation of capsid performance with therapeutic genetic payloads. Reporter expression provides useful evidence of vector delivery, but disease treatment depends on whether the introduced gene or regulatory sequence produces the intended biological effect. Each application will require evaluation in appropriate experimental systems.
Safety will be equally important. More efficient targeting may reduce certain unwanted exposures, but the complete risks of systemic or central nervous system AAV administration must still be assessed. Immune responses, liver effects, neurological toxicity and long-term expression all require product-specific evaluation.
Manufacturing feasibility represents another development requirement. Capsid modifications can influence production yields, purification and product stability, potentially affecting the commercial practicality of a promising laboratory candidate. Latus Bio must demonstrate that selected vectors can be manufactured consistently under the standards required for clinical use.
The company’s therapeutic programmes provide opportunities to test its broader platform claims. LTS-101 has already secured IND clearance, while LTS-201 is supported by a peer-reviewed preclinical and computational evidence package. The kidney capsids remain an earlier-stage platform opportunity without an announced disease-specific clinical trial.
Latus Bio has reported substantial improvements in cellular delivery across medically important tissues, particularly in primate models. The findings strengthen the case for engineered AAV capsids as enabling technologies but do not establish that the resulting gene therapies will be safer or more effective in patients. Their ultimate significance will depend on clinical evidence showing that precise delivery translates into meaningful, durable treatment benefit.
